Spots Global Cancer Trial Database for Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases
Official Title: Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases: a Retrospective Single-center Cohort Study
Study ID: NCT03717519
Interventions
Study Description
Brief Summary: Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients. In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chirurgia Generale ed Epatobiliare, Policlinico GB Rossi, Verona, , Italy
Contact Details
Name: Corrado Pedrazzani, MD
Affiliation: Azienda Ospedaliera Universitaria Integrata Verona
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
